natgillin/translations-raw huggingface dataset:
De hyppigst rapporterede bivirkninger i undersøgelser med Invega er hovedpine, søvnbesvær, søvnighed, parkinsonisme (neurologiske symptomer, herunder rysten og nedsat muskelkontrol), akatisi (rastløshed), takykardi (forøget hjertefrekvens), dystoni (ufrivillige muskelsammentrækninger), trækninger (rystelser), øvre luftvejsinfektioner (forkølelser), angst, svimmelhed, vægtforøgelse, kvalme, ophidselse, forstoppelse, opkastning, træthed, depression, dyspepsi (halsbrand), diarré, tør mund, tandpine, muskel- og knoglesmerter, asteni (kraftesløshed), forhøjet blodtryk, rygsmerter og forlænget QT på et elektrokardiogram (en ændring af den elektriske aktivitet i hjertet) og hoste.
The most frequently reported side effects in studies with Invega are headache, insomnia (difficulty sleeping), sleepiness, parkinsonism (neurological symptoms including tremor and impaired muscular control), akathisia (restlessness), tachycardia (increased heart rate), dystonia (involuntary muscle contractions), tremor (shaking), upper respiratory tract infection (colds), anxiety, dizziness, increased weight, nausea, agitation, constipation, vomiting, fatigue (tiredness), depression, dyspepsia (heartburn), diarrhoea, dry mouth, toothache, muscle and bone pain, asthenia (weakness), high blood pressure, back pain, prolonged electrocardiogram QT (an alteration of the electrical activity of the heart) and cough.
De hyppigst rapporterede bivirkninger med raltegravir var hovedpine og kvalme.
The most frequently reported adverse reactions during treatment with raltegravir were headache and nausea.
De hyppigst rapporterede bivirkninger under behandling med Xultophy var hypoglykæmi og gastrointestinale bivirkninger (se afsnittet "Beskrivelse af udvalgte bivirkninger" nedenfor).
The most frequently reported adverse reactions during treatment with Xultophy were hypoglycaemia and gastrointestinal adverse reactions (see section ‘Description of selected adverse reactions’ below).
De hyppigst rapporterede bivirkninger under behandling var hovedpine og kvalme, som forekom hos 5% eller mere.
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5 % or greater.
De hyppigst rapporterede bivirkninger under behandling var hovedpine og kvalme, som forekom hos 5% eller mere.
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5% or greater.
De hyppigst rapporterede bivirkninger under de kliniske undersøgelser med Esbriet var kvalme, udslæt, træthed, diarré, dyspepsi (halsbrand), appetitløshed, hovedpine og lysoverfølsomhedsreaktioner (reaktioner, der ligner solskoldethed, efter at have været udsat for lys).
The most commonly reported side effects during clinical study experience with Esbriet were nausea (feeling sick), rash, fatigue, diarrhoea, dyspepsia (heartburn), anorexia (loss of appetite), headache and photosensitivity reaction (sunburn-like reactions following exposure to light).
De hyppigst rapporterede bivirkninger var abdominalsmerter og abdominal distension (49 %), luftvejsinfektioner (28 %), kvalme (27 %), reaktioner på injektionsstedet (21 %), hovedpine (17 %), opkastning (14 %) og perifere ødemer (10 %).
The most commonly reported adverse reactions were abdominal pain and distension (49%), respiratory tract infections (28%), nausea (27%), injection site reactions (21%), headache (17%), vomiting (14%) and oedema peripheral (10%).
De hyppigst rapporterede bivirkninger var forbigående lokal brændende fornemmelse på applikationsstedet, smerter, erytem og pruritus.
The most commonly reported adverse reactions were transient local application site burning, pain, erythema and pruritus.
De hyppigst rapporterede bivirkninger var knoglesmerter (meget almindelig [≥ 1/10]) og muskuloskeletale smerter (almindelig).
The most frequently reported adverse reactions were bone pain (very common [ ≥ 1/10]) and musculoskeletal pain (common).
De hyppigst rapporterede bivirkninger var reaktioner ved injektionsstedet og øgede hepatiske enzymer.
The most frequently reported adverse reactions were injection site reactions, and hepatic enzymes increased.
De hyppigst rapporterede bivirkninger var reaktioner ved injektionsstedet, og øgede hepatiske enzymer.
The most frequently reported adverse reactions were injection site reactions, and hepatic enzymes increased.
De hyppigst rapporterede bivirkninger var træthed, hovedpine, pruritus, anæmi, influenza-lignende sygdom, kvalme, insomni, neutropeni, asteni, udslæt, nedsat appetit, tør hud, alopeci, pyreksi, myalgi, irritabilitet, hoste, diarre, dyspnø og artralgi.
The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza- like illness, nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability, cough, diarrhoea, dyspnoea and arthralgia.
De hyppigst rapporterede bivirkninger var utilpashed og træthed, luftvejsinfektioner, ubehag i hals og fra mandler, hovedpine, abdominalsmerter og -ubehag, kvalme, opkastning og diarré.
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
De hyppigst rapporterede bivirkninger ved behandling med 2 mg Resolor var hovedpine (17,8 %) og symptomer i mave-tarm-kanalen (abdominale smerter (13,7 %), kvalme (13,7 %) og diarré (12,0 %)).
The most frequently reported adverse reactions associated with Resolor 2mg therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain (13.7%), nausea (13.7%) and diarrhoea (12.0%)).
De hyppigst rapporterede bivirkninger ved behandling med 2 mg Resolor var hovedpine (17,8 %) og symptomer i mave-tarm-kanalen (abdominalsmerter (13,7 %), kvalme (13,7 %) og diarré (12,0 %)).
The most frequently reported adverse reactions associated with Resolor 2mg therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain (13.7%), nausea (13.7%) and diarrhoea (12.0%)).
De hyppigst rapporterede bivirkninger ved Incruse var nasopharyngitis og infektion i de øvre luftveje.
The most frequently reported adverse reactions with Incruse were nasopharyngitis and upper respiratory tract infection.
De hyppigst rapporterede bivirkninger, der blev set i fase 2b/3-studierne var kvalme, diarré, træthed og hovedpine.
The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fatigue and headache.
De hyppigst rapporterede bivirkninger, der blev set i fase 2b/3-studierne, var kvalme, diarré, træthed og hovedpine.
The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fatigue and headache.
De hyppigst rapporterede bivirkninger, som førte til seponering (>1%) hos patienter behandlet med Tecfidera, var rødme (3%) og gastrointestinale lidelser (4%).
The most commonly reported adverse reactions leading to discontinuation (incidence >1%) in patients treated with Tecfidera were flushing (3%) and gastrointestinal events (4%).
De hyppigst rapporterede blødninger (≥4 %) var epistaxis (5,9 %) og blødning fra mave-tarm-kanalen (4,2 %).
The most commonly reported bleedings (≥4 %) were epistaxis (5.9 %) and gastrointestinal tract haemorrhage (4.2 %).
De hyppigst rapporterede er læbespalte, kardiovaskulære misdannelser og defekt af neuralrøret.
The most frequently reported are cleft lip, cardiovascular malformations and neural tube defect.
De hyppigst rapporterede grad 3-4 reaktioner (≥5 % forekomst) med mindst 2 % højere forekomst for ZALTRAP/FOLFIRI-regimet end for placebo/FOLFIRI-regimet var, med faldende frekvens: neutropeni, diarré, hypertension, leukopeni, stomatitis, træthed, proteinuri og asteni (se Tabel 1).
The most common reported grades 3-4 reactions (≥5% incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency, were neutropenia, diarrhoea, hypertension, leucopenia, stomatitis, fatigue, proteinuria, and asthenia (see Table 1).
De hyppigst rapporterede hændelser med abatacept (1-2%) var svimmelhed, hovedpine og hypertension.
The most frequently reported events with abatacept (1-2%) were dizziness, headache, and hypertension.
De hyppigst rapporterede non-hæmatologiske bivirkninger var gastrointestinale f.eks. kvalme (52 %), opkastning (32 %) og diarre (18 %), obstipation (9 %) og mucositis (14 %).
Frequently reported non-haematological effects were gastrointestinal such as nausea (52 %), vomiting (32 %), and diarrhoea (18 %), constipation (9 %) and mucositis (14 %).
De hyppigst rapporterede symptomer på dyspnø var milde til moderate i styrke, og de fleste blev rapporteret som en enkelt episode kort efter behandlingsstart.
Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode early after starting treatment.
De hyppigst rapporterede uønskede blødningshændelser var konjunktivalblødning (op til 24 %).
The most common haemorrhagic adverse event reported was conjunctival haemorrhage (up to 24%).
De hyppigst rapporterede var hovedpine, kvalme, opkastning, diarré, smerter i abdomen, svimmelhed, rødmen og træthed.
Most frequently reported were headache, nausea, vomiting, diarrhoea, abdominal pain, dizziness, flushing and fatigue.
De hyppigst rapporterede var mouches volantes (uklarheder i glaslegemet), øjensmerter og fotopsi samt konjunktival blødning som følge af injektionsproceduren.
The most commonly reported were vitreous floaters, eye pain and photopsia, as well as conjunctival haemorrhage resulting from the injection procedure.
De hyppigst rapporterede årsager til seponering var cellulitis (0,4 %, 4/976) og osteomyelitis (0,3 %, 3/976).
The most common reported reasons for discontinuation were cellulitis (0.4%, 4/976) and osteomyelitis (0.3%, 3/976).
De hyppigst registrerede samtidige lægemidler for Parkinsons sygdom hos randomiserede patienter var dopaminagonister (64 %) og MAO-hæmmere (37 %).
The most frequently recorded concomitant medicinal products for Parkinson’s disease in randomized patients were dopamine agonists (64%), and MAO inhibitors (37%).
de hyppigste alvorlige bivirkninger (>0,5% af patienterne) var blødning, feber, dyspnø, muskuloskeletale smerter, trombocytopeni, abdominalsmerter og opkastning. ● de hyppigste bivirkninger (≥25%) var kvalme, træthed og hovedpine.
the most common serious ADRs (> 0.5% of patients) were haemorrhage, pyrexia, dyspnoea, musculoskeletal pain, thrombocytopenia, abdominal pain and vomiting. the most common adverse drug reactions (ADRs) (≥25%) with trastuzumab emtansine were nausea, fatigue, and headache.
De hyppigste alvorlige bivirkninger (≥ 2 %) ved ONIVYDE-behandlingen var diarré, opkastning, febril neutropeni, kvalme, pyreksi, sepsis, dehydrering, septisk shock, pneumoni, akut nyresvigt og trombocytopeni.
The most common serious adverse reactions (≥ 2%) of ONIVYDE therapy were diarrhoea, vomiting, febrile neutropenia, nausea, pyrexia, sepsis, dehydration, septic shock, pneumonia, acute renal failure, and thrombocytopenia.
De hyppigste alvorlige bivirkninger er cytopenier, infusionsreaktioner og immunsuppression/infektioner.
The most frequent serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.
De hyppigste alvorlige bivirkninger er febril neutropeni (lavt antal hvide blodlegemer (neutrofiler) og feber), svær diarré, leukopeni (lavt antal hvide blodlegemer) og neutropeni.
The most common serious side effects include febrile neutropenia (low levels of neutrophils with fever), serious diarrhoea, leucopenia (low white blood cell counts) and neutropenia.
De hyppigste alvorlige bivirkninger er mavesmerter, ophobning af væske i lungerne, diarré og kvalme.
The most common serious side effects are abdominal (belly) pain, pleural effusion (build-up of fluid around the lungs), diarrhoea and nausea.
De hyppigste alvorlige bivirkninger forbundet med cabozantinib er abdominalsmerter (3 %), pleuraeffusion (3 %), diarré (2 %) og kvalme (2 %).
The most common serious adverse reactions associated with cabozantinib are abdominal pain (3%), pleural effusion (3%), diarrhoea (2%), and nausea (2%).
De hyppigste alvorlige bivirkninger ved Iclusig (som kan optræde hos mere end 1 ud af 100 patienter) er lungebetændelse, pankreatitis (bugspytkirtelbetændelse), feber, mavesmerter, myokardieinfarkt (hjerteanfald), atrieflimren (uregelmæssige hurtige sammentrækninger af de øverste hjertekamre), anæmi (for lavt antal røde blodlegemer), nedsat antal blodplader (de blodkomponenter, der medvirker til blodets størkning), febril neutropeni (for lavt antal hvide blodlegemer og feber), hjerteinsufficiens (når hjertet ikke virker så godt som det burde), forhøjet indhold af lipase (et enzym), dyspnø (stakåndethed), diarré, nedsat antal neutrofiler (en type hvide blodlegemer), pancytopeni (generelt lavt antal blodceller) og perikardial effusion (væskeansamling omkring hjertet).
The most common serious side effects with Iclusig (which may affect more than 1 in 100 people) are pneumonia (infection of the lungs), pancreatitis (inflammation of the pancreas), pyrexia (fever), abdominal pain (stomach ache), myocardial infarction (heart attack), atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), anaemia (low red blood cell counts), decreased blood levels of platelets (components that help the blood to clot), febrile neutropenia (low white blood cell counts with fever), cardiac failure (when the heart does not work as well as it should), increased levels of lipase (an enzyme), dyspnoea (difficulty breathing), diarrhoea, decreased levels of neutrophils (a type of white blood cell), pancytopenia (low overall blood cell counts) and pericardial effusion (fluid around the heart).
De hyppigste alvorlige bivirkninger, som forekom med en frekvens ≥1% hos sildenafilpatienter (alle doser), var pneumoni (7,4%), hjertesvigt og pulmonal hypertension (hver 5,2%), infektion i øvre luftveje, (3,1%), svigt af højre ventrikel og gastroenteritis (hver 2,6%), synkope, bronkitis, bronkopneumoni og pulmonal arteriel hypertension (hver 2,2%), brystsmerter og dental caries (hver 1,7%) samt kardiogent shock, viral gastroenteritis og urinvejsinfektion (hver 1,3%).
The most common serious adverse events that occurred with a frequency ≥ 1 % in sildenafil patients (combined doses) were pneumonia (7.4%), cardiac failure, pulmonary hypertension (each 5.2%), upper respiratory tract infection (3.1%), right ventricular failure, gastroenteritis (each 2.6%), syncope, bronchitis, bronchopneumonia, pulmonary arterial hypertension (each 2.2%), chest pain, dental caries (each 1.7%), and cardiogenic shock, gastroenteritis viral, urinary tract infection (each 1.3%).
De hyppigste alvorlige og letale bivirkninger er major blødning (blødning på indstiksstedet og andre steder, herunder også intrakraniel blødning) og overfølsomhed, herunder også anafylaktisk shock.
The most frequent serious and fatal adverse reactions are major haemorrhage (access site and non access-site bleeding, including intracranial haemorrhage) and hypersensitivity, including anaphylactic shock.
De hyppigste behandlingsrelaterede bivirkninger, der er rapporteret under kliniske forsøg med PegIntron i kombination med ribavirin hos voksne, og som er set hos mere end halvdelen af forsøgspersonerne, var træthed, hovedpine og reaktion på injektionsstedet.
The most common treatment-related adverse reactions reported during clinical trials with PegIntron in combination with ribavirin in adults, seen in more than half of the study subjects, were fatigue, headache, and injection site reaction.
De hyppigste behandlingsrelaterede bivirkninger, der er rapporteret under kliniske forsøgr med PegIntron i kombination med ribavirin hos voksne, og som er set hos mere end halvdelen af forsøgspersonerne, var træthed, hovedpine og reaktion på injektionsstedet.
The most common treatment-related adverse reactions reported during clinical trials with PegIntron in combination with ribavirin in adults, seen in more than half of the study subjects, were fatigue, headache, and injection site reaction.
De hyppigste bivirkninger (> 5%) i de kontrollerede perioder i kliniske studier af ustekinumab hos voksne med psoriasis, psoriasisartrit eller Crohns sygdom var nasopharyngitis og hovedpine.
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn’s disease clinical studies with ustekinumab were nasopharyngitis and headache.
De hyppigste bivirkninger (> 5%) i de kontrollerede perioder i kliniske studier af ustekinumab mod psoriasis, psoriasisartrit og Crohns sygdom hos voksne var nasopharyngitis og hovedpine.
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis and Crohn’s disease clinical studies with ustekinumab were nasopharyngitis and headache.
De hyppigste bivirkninger (>20%), som blev observeret ned højere frekvens i placebo-plus- vemurafenib-armen, var artralgi, alopeci og hyperkeratose.
The most common adverse reactions (>20%) observed with a higher frequency in the placebo plus vemurafenib arm were arthralgia, alopecia, and hyperkeratosis.
De hyppigste bivirkninger (>20%), som ses ved behandling med axitinib er diarré, hypertension, træthed, nedsat appetit, kvalme, vægttab, dysfoni, palmo-plantar erytrodysæstesi (hånd- og fodsyndrom), blødning, hypotyreose, opkastning, proteinuri, hoste og obstipation.
The most common (≥ 20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar- plantar erythrodysaesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.
De hyppigste bivirkninger (ADR’er) var: hovedpine, kvalme, mavesmerter, udslæt, artralgi, rygsmerter, smerter i ekstremiteter, flushing, pyrexi, reaktioner på infusionsstedet, forhøjet blodtryk, nedsat iltmætning, takykardi og kulderystelser.
The most frequent adverse drug reactions (ADRs) were: headache, nausea, abdominal pain, rash, arthralgia, backpain, pain at extremity, flushing, pyrexia, infusion site reactions, blood pressure increased, oxygen saturation decreased, tachycardia and chills.
De hyppigste bivirkninger (der ses hos mellem 1 og 10 patienter ud af 100) er, hos børn, forbigående lokale hudreaktioner på injektionsstedet; og hos voksne, let ødem (væskeansamling), paræstesi (følelsesløshed eller snurren), smerter i led og muskler (specielt i hofte eller knæ) og stivhed i arme og ben.
The most common side effects (seen in between 1 and 10 patients in 100) are, in children, transient local skin reactions at the site of injection, and in adults, mild oedema (accumulation of fluid), paraesthesia (numbness or tingling), joint and muscle pain (especially in the hip or knee) and stiffness of the limbs.
De hyppigste bivirkninger (forekom hos > 20 % af patienterne) var: anæmi, træthed, diaré, trombocytopeni, nausea, pyreksi, dyspnø, luftvejsinfektion, hoste og perifert ødem.
The most common adverse reactions (occurring in > 20% of subjects) were: anaemia, fatigue, diarrhoea, thrombocytopenia, nausea, pyrexia, dyspnoea, respiratory tract infection, cough and peripheral oedema.
De hyppigste bivirkninger (forekomst ≥10 %) af Gilenya 0,5 mg var influenza,sinusitis, hovedpine, diaré, rygsmerter, leverenzymforhøjelse og hoste.
The most frequent adverse reactions (incidence ≥10%) on Gilenya 0.5 mg were influenza, sinusitis, headache, diarrhoea, back pain, hepatic enzyme increased and cough.
De hyppigste bivirkninger (hyppighed ≥1/10) fra puljede sikkerhedsdata fra fase III-studierne C2305 og C2402 var (i rækkefølge med faldende hyppighed): diarré (hyppigst i C2305-studiet), cholelithiasis, hyperglykæmi (hyppigst i C2402-studiet) og diabetes mellitus.
The most common adverse reactions (incidence ≥1/10) from the pooled safety data from the phase III studies C2305 and C2402 were (in decreasing order): diarrhoea (most common in study C2305), cholelithiasis, hyperglycaemia (most common in study C2402) and diabetes mellitus.
De hyppigste bivirkninger (incidens ≥ 20 %) ved ONIVYDE + 5-FU/LV var diarré, kvalme, opkastning, appetitløshed, neutropeni, træthed, asteni, anæmi, stomatitis og pyreksi.
The most common adverse reactions (incidence ≥ 20%) of ONIVYDE+5FU/LV were: diarrhoea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anaemia, stomatitis and pyrexia.
De hyppigste bivirkninger (incidens ≥1/10 og af investigatoren formodet relateret til behandlingen) fra de samlede sikkerhedsdata er (i rækkefølge med faldende incidens): stomatitis, infektion i øvre luftveje, amenoré, hyperkolesterolæmi, nasopharyngitis, akne, uregelmæssig menstruation, sinuitis, otitis media og pneumoni.
The most frequent adverse reactions (incidence ≥1/10 and suspected by the investigator to be related to treatment) from the pooled safety data are (in decreasing order): stomatitis, upper respiratory tract infections, amenorrhoea, hypercholesterolaemia, nasopharyngitis, acne, menstruation irregular, sinusitis, otitis media and pneumonia.
De hyppigste bivirkninger (som optræder hos mere end 1 ud af 10 patienter) ved Exviera anvendt sammen med Viekirax og ribavirin er søvnløshed, kvalme, kløe (pruritus), svaghed (asteni) og træthed.
The most common side effects with Exviera when used with Viekirax and ribavirin (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea, pruritus (itching), asthenia (weakness) and fatigue (tiredness).
De hyppigste bivirkninger (som optræder hos mere end 1 ud af 10 patienter) ved Viekirax anvendt sammen med dasabuvir og ribavirin er søvnløshed, kvalme, kløe (pruritus), svaghed (asteni) og træthed.
The most common side effects with Viekirax in combination with dasabuvir and ribavirin (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea, pruritus (itching), asthenia (weakness) and fatigue (tiredness).
De hyppigste bivirkninger (≥ 10%) i de puljede datasæt for nivolumab 3 mg/kg som monoterapi på tværs af tumortyper (CA209066, CA209037, CA209067 (monoterapigruppe), CA209017, CA209057, CA209063 og CA209025) var træthed (34%), udslæt (19%), pruritus (14%), diarre (13%), kvalme (13%) og appetitløshed (10%).
In the pooled dataset of nivolumab 3 mg/kg as monotherapy across tumour types (CA209066, CA209037, CA209067 (monotherapy group), CA209017, CA209057, CA209063 and CA209025), the most frequent adverse reactions (≥ 10%) were fatigue (34%), rash (19%), pruritus (14%), diarrhoea (13%), nausea (13%), and decreased appetite (10%).
De hyppigste bivirkninger (≥ 20 %) var diarré, neutropeni, blødning (f.eks. blå mærker), muskuloskeletale smerter, kvalme, udslæt og pyreksi.
The most commonly occurring adverse reactions (≥ 20%) were diarrhoea, neutropenia, haemorrhage (e.g., bruising), musculoskeletal pain, nausea, rash, and pyrexia.
De hyppigste bivirkninger (≥ 20 %) ved kombinationsbehandling med dabrafenib og trametinib er pyreksi, træthed, kvalme, hovedpine, kulderystelser, diarré, udslæt, artralgi, hypertension, opkastning og hoste.
The most common adverse reactions (20%) for dabrafenib and trametinib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
De hyppigste bivirkninger (≥ 20 %) ved kombinationsbehandling med trametinib og dabrafenib er pyreksi, træthed, kvalme, hovedpine, kulderystelser, diarré, udslæt, artralgi, hypertension, opkastning og hoste.
The most common adverse reactions (≥ 20 %) for trametinib and dabrafenib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
De hyppigste bivirkninger (≥ 50 %) ved Perjeta i kombination med trastuzumab og docetaxel var diarré, alopeci og neutropeni.
The most common ADRs (≥ 50%) seen with Perjeta in combination with trastuzumab and docetaxel were diarrhoea, alopecia and neutropenia.